Corcept Therapeutics Incorporated

NasdaqCM:CORT 株式レポート

時価総額：US$5.9b

Corcept Therapeutics マネジメント

マネジメント 基準チェック /34

Corcept Therapeuticsの CEO はJoseph Belanoffで、 Jan1999年に任命され、 の在任期間は 25.83年です。 の年間総報酬は$ 9.34Mで、 11.6%給与と88.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の2.88%を直接所有しており、その価値は$ 169.52M 。経営陣と取締役会の平均在任期間はそれぞれ4年と23.1年です。

主要情報

Joseph Belanoff

最高経営責任者

US$9.3m

報酬総額

CEO給与比率11.6%
CEO在任期間25.8yrs
CEOの所有権2.9%
経営陣の平均在職期間4yrs
取締役会の平均在任期間23.1yrs

経営陣の近況

Recent updates

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

Sep 28
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Sep 06
If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

Aug 01
Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

Apr 15
With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Feb 22
We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Corcept Therapeutics: Key Catalysts Ahead

Feb 19

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Dec 23
After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Nov 07
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Jun 23
Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Feb 16
Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Jan 11
Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Corcept Therapeutics starts phase 2 trial of its ALS treatment

Oct 11

Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Sep 27
Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

CEO報酬分析

Corcept Therapeutics の収益と比較して、Joseph Belanoff の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

US$140m

Jun 30 2024n/an/a

US$125m

Mar 31 2024n/an/a

US$117m

Dec 31 2023US$9mUS$1m

US$105m

Sep 30 2023n/an/a

US$91m

Jun 30 2023n/an/a

US$94m

Mar 31 2023n/an/a

US$94m

Dec 31 2022US$7mUS$896k

US$101m

Sep 30 2022n/an/a

US$117m

Jun 30 2022n/an/a

US$113m

Mar 31 2022n/an/a

US$112m

Dec 31 2021US$11mUS$844k

US$113m

Sep 30 2021n/an/a

US$106m

Jun 30 2021n/an/a

US$98m

Mar 31 2021n/an/a

US$99m

Dec 31 2020US$6mUS$770k

US$106m

Sep 30 2020n/an/a

US$109m

Jun 30 2020n/an/a

US$114m

Mar 31 2020n/an/a

US$106m

Dec 31 2019US$5mUS$708k

US$94m

Sep 30 2019n/an/a

US$87m

Jun 30 2019n/an/a

US$78m

Mar 31 2019n/an/a

US$76m

Dec 31 2018US$6mUS$680k

US$75m

Sep 30 2018n/an/a

US$152m

Jun 30 2018n/an/a

US$148m

Mar 31 2018n/an/a

US$142m

Dec 31 2017US$4mUS$647k

US$129m

報酬と市場: Josephの 総報酬 ($USD 9.34M ) は、 US市場 ($USD 7.94M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Josephの報酬は過去 1 年間で 20% 以上増加しました。

CEO（最高経営責任者

Joseph Belanoff (67 yo)

25.8yrs

在職期間

US$9,337,734

報酬

Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Joseph Belanoff
Co-Founder25.8yrsUS$9.34m2.88%
$ 169.5m
Atabak Mokari
CFO & Treasurer3.7yrsUS$3.72m0.012%
$ 702.3k
Sean Maduck
President of Endocrinology8.6yrsUS$3.91m0.10%
$ 5.9m
William Guyer
Chief Development Officer3.3yrsUS$3.86m0.0055%
$ 325.0k
Gary Robb
Chief Business Officer & Secretary10.8yrsUS$3.96m0.040%
$ 2.4m
Joseph Lyon
Chief Accounting & Technology Officer4.3yrsデータなし0.0095%
$ 555.4k
Hazel Hunt
Chief Scientific Officer4.3yrsUS$3.11m0.11%
$ 6.7m
Amy Flood
Chief Human Resources & Communications Officer3.3yrsデータなしデータなし
Monica Tellado
President of Emerging Marketsless than a yearデータなしデータなし
Roberto Vieira
President of Oncologyless than a yearデータなしデータなし

4.0yrs

平均在職期間

53.5yo

平均年齢

経験豊富な経営陣: CORTの経営陣は 経験豊富 であると考えられます ( 4年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Joseph Belanoff
Co-Founder25.8yrsUS$9.34m2.88%
$ 169.5m
George Baker
Independent Director25.8yrsUS$492.53k5.07%
$ 297.8m
David Mahoney
Independent Director20.3yrsUS$509.03k1.25%
$ 73.7m
Charles Nemeroff
Member of Scientific Advisory Boardno dataデータなしデータなし
James Wilson
Independent Chairman25.8yrsUS$1.26m2.11%
$ 124.2m
Florian Holsboer
Member of Scientific Advisory Boardno dataデータなしデータなし
Bruce McEwen
Member of Scientific Advisory Boardno dataデータなしデータなし
Ned Kalin
Member of Scientific Advisory Boardno dataデータなしデータなし
Edo Kloet
Member of Scientific Advisory Boardno dataデータなしデータなし
Gregg Alton
Independent Director4.7yrsUS$511.53k0%
$ 0
K. Ranga Krishnan
Member of Scientific Advisory Boardno dataデータなしデータなし
Kimberly Park
Independent Director5.2yrsUS$488.53k0%
$ 0

23.1yrs

平均在職期間

68.5yo

平均年齢

経験豊富なボード: CORTの 取締役会 は経験豊富で 経験豊富 です ( 23.1年の平均在任期間)。